ArticleFrontiers in cellular and infection microbiology2026
Application of multi-channel magnetic particle immunofluorescent disc microfluidic chip for combined detection of antibodies against six common infectious diseases including visceral leishmaniasis in pastoral areas.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to develop a microfluidic chip for the simultaneous detection of specific antibodies against six common pathogens in pastoral areas. The specific detection targets include: visceral leishmaniasis (IgG against Methods: Based on magnetic particle immunofluorescence, a multi-channel disc microfluidic chip and reagents were designed. Parameters (antigen-antibody microsphere ratio, sample dilution) were optimized; fluid dynamics tests verified fluid operation feasibility. Serum samples from patients with the six diseases and healthy controls were used to detect target antibodies. The chip's accuracy, dose-response curve (R Results: The chip exhibited normal fluidic operation. Optimized reagents/samples enhanced utilization efficiency. For the six diseases, the detection accuracy met the requirements: the coefficient of determination (R Conclusions: This chip exhibits stable fluid flow, low sample/reagent consumption, and excellent accuracy/precision/specificity. Its detection results are consistent with those of traditional methods, and it enables the simultaneous combined detection of the aforementioned six infectious diseases. Compared with the clinically used method (enzyme-linked immunosorbent assay, ELISA), this chip has greater advantages in application scenarios and comprehensive benefits; compared with existing disc-based microfluidic technologies, it holds superior advantages in terms of detection throughput and application objectives. It provides a rapid, sensitive, and specific technical tool for the acute-phase screening, disease course confirmation, infection staging, differentiation between bacterial and parasitic infections, and disease prognosis detection of multiple prevalent infectious diseases in pastoral areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.